High-risk patients with heart failure with preserved ejection fraction (HFpEF) who have obesity and Type 2 diabetes experienced over a 40% lower risk of hospitalization or death after initiating semaglutide or tirzepatide compared to placebo by proxy. HFpEF involves preserved pumping ability but a thick, stiff heart muscle that limits effective blood output and is common in obesity and diabetes. GLP-1 receptor agonists semaglutide and tirzepatide provide weight loss and glycemic control and may also reduce heart failure hospitalizations and all-cause mortality in this population based on real-world data from more than 90,000 patients.
"Despite the widespread morbidity and mortality burden of HFpEF, current treatment options are limited," said corresponding author Nils Krüger of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital and a postdoctoral research fellow at Harvard Medical School. "Both semaglutide and tirzepatide are well-known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and Type 2 diabetes by reducing adverse heart failure outcomes."
Specifically, researchers looked at heart failure with preserved ejection fraction (HFpEF), a condition where the heart's ability to pump remains intact, yet the heart's muscle has become so thick and stiff that the amount of blood being pumped doesn't meet the body's needs. This form of heart failure is especially common among people with obesity and Type 2 diabetes.
By analyzing real-world data from over 90,000 HFpEF patients with obesity and Type 2 diabetes, researchers from MGB demonstrated that GLP-1 medications may significantly reduce the risk of hospitalization due to heart failure and all-cause mortality. Findings are published in JAMA and presented simultaneously at the European Society of Cardiology Congress.
Collection
[
|
...
]